

## Multiple myeloma with multilobated plasma cell nuclei

### *Çok çekirdekli plazma hücreli Multipl Miyelom*

Nergiz Erkut<sup>1</sup>, Ümit Çobanoğlu<sup>2</sup>, Mehmet Sönmez<sup>1</sup>

<sup>1</sup>Department of Haematology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey

<sup>2</sup>Department of Pathology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey

A 61-year-old male patient was admitted to our hospital with backache and fatigue. Physical examination was normal, except for pallor. Laboratory results at initial evaluation were as follows: hemoglobin: 105 g L; hematocrit: 0.31%; white blood cell (WBC) count:  $6.3 \times 10^9$  L; platelet count:  $200 \times 10^9$  L; blood urea nitrogen (BUN): 22.1 mmol L; creatinine:  $477.3 \mu\text{mol}$  L; calcium: 2.8 mmol L; total protein: 74 g L; albumin: 43 g L; erythrocyte sedimentation rate (ESR):  $44 \text{ mm h}^{-1}$ . A monoclonal spike was present on protein electrophoresis. Protein studies (by nephelometry) showed a kappa light chain of 5.97 g L (reference range: 1.7-3.7 g L) and low levels of IgG, IgM, and IgA (8.84 g L, 0.30 g L, 0.53 g L, respectively). Beta 2 microglobulin was 1.2 mg dL (reference range: 0.07-0.19 mg dL). Urine immunoelectrophoresis showed that the patient had a kappa monoclonal light chain. Bone X-rays showed multiple osteolytic lesions. The bone marrow aspirate and biopsy specimen morphology showed infiltration by atypical and multilobated plasma cell nuclei (Figures 1 and 2). The bone marrow biopsy specimen stained positive with CD138 (Figure 3).

Multiple myeloma with multinucleated plasma cells is a rare morphological variant, which usually presents with light chain expression, and is charac-




Figure 1. Atypical and multinucleated plasma cell infiltration in bone marrow aspirate





Figure 2. Atypical and multinucleated plasma cell infiltration in the bone marrow biopsy specimen



**Figure 3.** Kappa light chain-positive bone marrow biopsy specimen

terized by an aggressive course and resistance to conventional chemotherapy [1,2]. Informed consent was obtained from the patient.

#### **Conflict of interest statement**

The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

#### **References**

1. Fonseca R, San Miquel J. Prognostic factors and staging in multiple myeloma. *Hematol Oncol Clin North Am.* 2007;21:1115-40.
2. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. *Leukemia.* 2009;23:3-9.